Abstract:Abstract Abstract 4010 Poster Board III-946 Introduction Interaction of glycoprotein (GP) Ibα with Von Willebrand factor (VWF) plays a critical role in platelet adhesion and signal transduction for αIIbβ3 activation under condition of high shear stress. Methods Based on the crystal structure of platelet GPIbα (PDB:1P9A), virtual screening was employed to identify active compounds. Compounds in SPECS database were docked to VWF binding site on the surface of GPIbα. The screening was carried out with the DOCK4.0 program. The 150 highest-scoring compounds were obtained for further bioassay and those with inhibitory activity of VWF binding to GPIbα were investigated the effect on platelet activation and aggregation. Results We found one compound, designated it as YC148, blocked ristocetin-induced plasma VWF binding to recombinant N-terminal fragment GPIbα (H1-V289) by ELISA method. More interestingly, YC148 did not inhibit ristocetin-induced platelet aggregation, on the contrary, it induced platelet aggregation itself in the absence of exogenous modulators such as ristocetin and botrocetin. A VWF A1 blocking antibody could not block platelet aggregation induced by YC148 despite it completely inhibited ristocetin-induced platelet agglutination. And YC148 also stimulated washed platelet aggregation where VWF was absent in the resuspension buffer. These indicated that the aggregation stimulated by YC148 could not the result from VWF binding. Flow cytomety also showed that YC148 increased P-selectin expression on platelet membrane and promoted monoclonal antibody PAC-1 binding to platelet. The platelet aggregation stimulated by YC148 was inhibited by anti-GPIbα monoclonal antibody AN51 and 6D1. Conclusion A novel exogenous small-molecule agonist was found to activate platelet through binding to GPIbα. It provides us a new tool for investigating platelet GPIb outside-in signaling pathway in platelet adhesion and aggregation. Furthermore, the structure of YC148 may provide a structural basis for developing new hemostatic drugs based on the inhibition of VWF-GPIb interaction. The effect of YC148 on platelet from Bernard-Soulier syndrome or GPIbα N-terminal fragment deficient platelet after in vitro cleavage will be further investigated. Disclosures: No relevant conflicts of interest to declare.

A Novel Platelet Small-Molecule Agonist Targeting Glycoprotein Ibalpha

Discovery of novel antagonists of glycoprotein IIb/IIIa-mediated platelet aggregation through virtual screening.

A Novel Anti-Platelet Peptide (Z4A5) Potential for Glycoprotein IIb/IIIa Inhibits Platelet Aggregation

Novel GPIb-independent platelet aggregation induced by botrocetin: Implications for diagnosis and antithrombotic therapy

Distinct platelet interactions with soluble and immobilized von Willebrand factor modulate platelet adhesion and aggregation with differential impact on hemostasis and thrombosis

Essential role of glycoprotein Ibα in platelet activation

A critical role for the regulation of Syk from agglutination to aggregation in human platelets

Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets

Design, Synthesis and Evaluation of Novel 2-Amino-3-(naphth-2-yl)propanoic Acid Derivatives As Potent Inhibitors of Platelet Aggregation

Modulation Of Platelet Activation And Thrombus Formation Using A Pan-Pi3k Inhibitor S14161

Targeting Platelet GPIbβ Reduces Platelet Adhesion, GPIb Signaling and Thrombin Generation and Prevents Arterial Thrombosis

How Does Agkicetin-C Bind on Platelet Glycoprotein Ib Alpha and Achieve Its Platelet Effects?

Structural basis for the specific inhibition of glycoprotein Ibα shedding by an inhibitory antibody

Engineering and Characterization of a Chimeric Anti-platelet Glycoprotein Ibα Monoclonal Antibody and Preparation of Its Fab Fragment

Engineering and Characterization of A Chimeric Anti-Platelet Glycoprotein Ib Alpha Monoclonal Antibody and Preparation of Its Fab Fragment

Structure of the platelet glycoprotein Ib receptor in complex with a novel antithrombotic agent

WY-14643, a novel antiplatelet and antithrombotic agent targeting the GPIbα receptor

A Mechanism for Localized Dynamics-driven Affinity Regulation of the Binding of Von Willebrand Factor to Platelet Glycoprotein Ibα*

Shear-induced Interaction of Platelets with Von Willebrand Factor Results in Glycoprotein Ibalpha Shedding.

The Α1 Helix-Β13 Strand Spanning Leu214 to Val229 of Platelet Glycoprotein Ibα Facilitates the Interaction with Von Willebrand Factor: Evidence from Characterization of the Epitope of Monoclonal Antibody AP1

Development,identification and Function Assay of Monoclonal Antibody Against Platelet Membrane Glycoprotein Ib